Maori v. Maori

2002 DNH 089
District Court, D. New Hampshire·Decided May 1, 2002·No. CV-01-464-JD·Published·Cited by 1 cases

Opinion

Maori v. Maori CV-01-464-JD 05/01/02 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW HAMPSHIRE

Vincent J. Maori and Ecruichem Research Institute, Ltd.

v. Civil No. 01-464-JD Opinion No. 2002 DNH 089

James N. Maori and NTD Labs., Inc.

O R D E R

The plaintiffs, Vincent Macri and Equichem Research Institute, Ltd., bring an action arising out of their failed business relationship with the defendants, James Macri and NTD Labs. The plaintiffs allege claims of misappropriation, unfair competition, unjust enrichment, breach of contract, and copyright infringement. The plaintiffs also seek injunctive relief. The defendants move to dismiss the action, asserting that the court lacks personal jurisdiction and that the plaintiffs failed to state a claim for which relief can be granted, pursuant to Federal Rules of Civil Procedure 12(b) (2) and 12(b) (6). Alternatively, the defendants move to transfer the action to the United States District Court for the Eastern District of New York, pursuant to 28 U.S.C. § 1404(a).

Background1

Defendant NTD, a New York corporation located in Huntington Station, New York, was founded in 1983. The parties dispute whether NTD was founded independently by the defendant, James Macri ("James"), or co-founded with his brother, the plaintiff, Vincent Macri ("Vincent"). Since at least 1990, however, Vincent and James equally owned and operated NTD, serving as officers and directors. At that time, both James and Vincent were New York residents with homes in Oyster Bay.

NTD engaged in the research and development of technologies for prenatal screening tests for Down Syndrome and other chromosomal abnormalities. The screening test method developed by NTD is known as the "Free Beta" method. NTD consequently developed computer apparatus and software technology for implementing Free Beta tests. The software used for the Free Beta tests is known as "ScreenLab." James, who has a doctorate in medical sciences, is the inventor, and patents in his name have been obtained or are pending on several NTD innovations.

Because of their inability to continue working together, Vincent entered into a written agreement with James in May of

1 For the purposes of this motion only, the facts are taken from the plaintiffs' complaint and the affidavits and supporting materials submitted by the parties.

1993 to transfer his 50% of the NTD shares to James, giving him 100% ownership of NTD ("Master Agreement"). In exchange, Vincent received 100% ownership of Equichem Research Institute, Ltd. ("Equichem NY"), which had been a wholly-owned subsidiary of NTD, incorporated in New York. Under the terms of the Master Agreement, Equichem NY would receive an exclusive royalty-free license to sublicense, sell, or otherwise exploit ScreenLab. In turn, Equichem NY issued to NTD a royalty-free right to use ScreenLab internally. The Master Agreement provided that Vincent would have the same right as NTD and/or James in the Free Beta technology, and that James and NTD would render reasonable assistance to Vincent and Equichem NY in obtaining patents for ScreenLab. The Master Agreement further provided for bimonthly payments to Vincent, commencing in June of 1993 and continuing until May of 2003, with a decrease in the amount of the payments taking effect after the first three years.

In June of 1993, the brothers executed five related agreements to implement the Master Agreement. James executed a Quitclaim Assignment that transferred to Equichem NY the entire right, title and interest in the ScreenLab software and Down's syndrome detection program developed by NTD as well as all rights in American and European patents and patent applications for ScreenLab technology. The parties entered into a License

Agreement that granted NTD and James a non-exclusive royalty-free license to use, copy, reproduce, modify, improve, and enhance the software assigned to Equichem NY. The License Agreement expressly prohibits James and NTD from selling, licensing or sublicensing, or otherwise exploiting the software. The Other Products Agreement ("Products Agreement") grants to Equichem NY a non-exclusive license to sublicense, sell, and otherwise exploit other NTD technology products.2 Another agreement ("Free Beta Agreement") provides that Vincent shall have the same legal and equitable rights to use Free Beta Technology as James and NTD, even though James is the developer and patent holder for the technology. The Free Beta Agreement authorizes James to license Free Beta technology to Eastman Kodak, with one-half of any licensing payments to be paid to Vincent directly. Both James and Vincent agreed to be bound by any such licensing agreement. An additional agreement ("Consulting Agreement") provides that Vincent will be available to NTD for consulting to the extent his services do not impede his performance with Equichem NY. The

2 The Products Agreement refers to specific technology listed in "schedule 1" annexed to the agreement. The court did not find "schedule 1" among the materials submitted by the plaintiffs. The terms of the Products Agreement provide that NTD will make periodic payments to Equichem NY towards the marketing, research and commercialization of the schedule 1 products, and Equichem NY will pay royalties to NTD for licensing fees received from the schedule 1 products.

Consulting Agreement reiterates the compensation terms of the Master Agreement, which states that Vincent will be paid $13,104 per month, for thirty-five months and $11,021 per month, for the next eighty-four months, on a bimonthly basis.

The Master Agreement and related agreements were fully negotiated and executed in the state of New York in May and June of 1993. Only the Consulting Agreement, License Agreement, and Products Agreement contain choice-of-law clauses, which state that the agreements are to be governed by the laws of New York. None of the agreements contains a forum selection clause.

At the time of the parties' agreements, NTD had been negotiating with Eastman Kodak to license Free Beta technology and ScreenLab software. In March of 1994, Kodak was granted an exclusive license by NTD for Free Beta and a non-exclusive license by Equichem NY for the use of ScreenLab. Kodak subsequently sold its clinical laboratory business to Johnson & Johnson, which assumed the licenses for Free Beta and ScreenLab. In 1999, Johnson & Johnson's Free Beta license became non­ exclusive .

At some point in 1994, Vincent and his family moved to New Hampshire. In 1995, Equichem Research Institute, Ltd. was

incorporated by Vincent in New Hampshire ("Equichem NH").3 The plaintiffs characterize Equichem NH as the "successor" company to Equichem NY. Although the defendants now dispute that designation, the parties continued their business relationship with James and NTD operating in New York, and Vincent and Equichem NH operating in New Hampshire.

In April of 1996, James wrote Vincent to suggest changes to the Consulting Agreement, for unspecified reasons. Within a week, Vincent responded to James's proposals with a signed agreement amending the Master Agreement and the Consulting Agreement ("1996 Amendment"). The 1996 Amendment states that Vincent's salary will remain at its current level, instead of decreasing after three years pursuant to the Consulting Agreement, and it extends his salary payments to August of 1994, over one year beyond the time frame established in the Master and Consulting Agreements. The 1996 Amendment also provides that James and Vincent agree to meet twice monthly in Boston or another mutually convenient location, and that NTD will pay Vincent an annual retirement benefit to be determined by James, as well as $700 per month for health insurance, until 2004. James signed the agreement in New York.

3 According to the defendants, Equichem NY was not dissolved until 1998 .

Free access — add to your briefcase to read the full text and ask questions with AI

Maori v. Maori, 2002 DNH 089 (D.N.H. 2002).

2002 DNH 089 (Maori v. Maori) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related